A carregar...
A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
Phosphatidylinositol 3-kinase δ (PIK3δ) is a tyrosine kinase essential for B cell survival, making it an important target in the treatment of chronic lymphocytic leukemia. Idelalisib is an inhibitor of PIK3δ demonstrating initial success in disease response, but is now shown to have a decreased over...
Na minha lista:
| Publicado no: | J Investig Med High Impact Case Rep |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5446100/ https://ncbi.nlm.nih.gov/pubmed/28589155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2324709617711463 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|